ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibitionPaul G. Kemps, Brianna Empringham, D. A. Evseev et al.|Blood|2021Cited by 157
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM. Emmy M. Dolman, Jan J. Molenaar, Evon Poon et al.|Clinical Cancer Research|2015Cited by 69
Supplementary Figure Legends from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM. Emmy M. Dolman, Jan J. Molenaar, Evon Poon et al.|Unknown|2023Cited by 0
Supplementary figures S1-8 from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM. Emmy M. Dolman, Jan J. Molenaar, Evon Poon et al.|Unknown|2023Cited by 0
Supplementary Tables S1-3 from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM. Emmy M. Dolman, Jan J. Molenaar, Evon Poon et al.|Unknown|2023Cited by 0